4 Active Stocks to Watch on Monday 👀

Stocks posted mixed results on Friday and closed last week with losses. The Dow gained 0.5%, while the S&P 500 added 0.2%, but the Nasdaq slid to a 0.6% loss. The small-cap Russell 2K also closed with a small 0.1% gain.

Index futures are inching higher in early-morning trading. S&P 500 are currently up 0.3%.

💵 Dollar Creeps Higher: The WSJ Dollar Index, which measures the USD against a basket of major currencies, is showing strength ahead of the opening bell. It's up about 0.89% from last week's lows.

Better-than-expected earnings are lifting shares of Check Point Software.

This morning, the Israeli company reported its Q4 results early this morning, and the results beat the Street's expectations.

Check Point generated earnings of $2.45 per share on revenues of $638 million.

Consensus estimates called for EPS of $2.36 on revenues of $636 million, according to data from Refinitiv.

CEO Gil Shwed said, "For the mid- and long-term range, it's actually going to remain a good environment for cyber and a good environment for Check Point."

CHKP is up 4.5% in the premarket on the heels of the strong quarterly report.

My Take: Check Point's strong earnings could be a signal that demand for cybersecurity and related services remain strong, despite the uncertain outlook for other sectors of the economy.

IMV is up after a promising clinical update.

The clinical-stage immuno-oncology stock announced positive preliminary data from a VITALIZE Phase 2B trial evaluation of a maveropepimut-S combo therapy.

The study examined maveropepimut-S in combination with pembrolizumab in certain types of lymphoma patients, and it produced notable results.

IMV said a preliminary analysis revealed clinically meaningful activity in relapsed, refractory Diffuse Large B Cell Lymphoma (DLBCL) patients.

Multiple confirmed complete responses observed, and the drug appears to be safe and tolerable.

IMV is one of today's top premarket performers with a 23.7% gain.

My Take: This drug appears to be showing promise, and it could be headed for an approval down the road.

Clene is also moving higher after an upbeat drug data release.

The clinical-stage pharma firm reported new data from a VISIONARY-MS Phase 2 study of CNM-Au8 in multiple sclerosis (MS) patients.

Clene reported MRI results reinforced neurological improvements noted in previous studies and demonstrated improved neuronal structural integrity.

The company noted that the brain improvements observed in stable MS Patients on background therapy were "unprecedented."

Shares of CLNN are up 47.4% on the clinical update, and the stock is trading actively in the premarket.

My Take: CLNN has been trading sideways for about a month, but this rally could help it break into a new trend line.

Ocular Therapeutics's latest drug data release is pushing shares higher.

On Saturday, the biopharma company unveiled interim 10-month data from a Phase 1 trial of OTX-TKI in patients with retinal diseases.

Ocular says the intravitreal hydrogel implant was safe and well tolerated in a 21-subject trial, and produced no serious adverse events through month 10.

Subjects treated with the implant demonstrated a 92% reduction in treatment burden.

Ocular says it plans to meet with the FDA to discuss future trial designs in the weeks ahead, and it intends to initiate a pivotal trial in Q3 of 2023.

OCUL is up 13.7% on the promising Phase 1 data.

My Take: OCUL could benefit from additional catalysts stemming from OTX-TKI's continued development. If the implant can gain full approval, there could be more gains in this stock's future.

Blue Owl Capital Inc. [OWL] ... AM
Check Point Software Technologies Ltd. [CHKP] ... AM
Cadence Design Systems, Inc. [CDNS] ... PM
Arista Networks, Inc. [ANET] ... PM
Arch Capital Group Ltd. [ACGL] ... PM
Firstenergy Corp. [FE] ... PM
Nu Holdings Ltd. [NU] ... PM
Solaredge Technologies, Inc. [SEDG] ... PM
Palantir Technologies Inc. [PLTR] ... PM
Avis Budget Group, Inc. [CAR] ... PM